Osteopenia
Osteopenia, or "low bone mass," is a condition characterized by decreased bone mineral density that weakens bones and increases the risk of fractures, but is not as severe as osteoporosis. It often occurs with aging and can be influenced by lifestyle, genetics, medication, or other health conditions; it typically does not cause symptoms or pain.
Health Outcomes
- Decreased Hydroxyapatite Integrity
- Delayed Osteoporosis Progression
- Improved Acceptability of Dairy Products
- Improved Bone Formation
- Improved Bone Mass Density
- Improved Bone Metabolism
- Improved Bone Microstructure
- Improved Bone Mineral Content
- Improved Bone Mineral Density
- Improved Bone Preservation
- Improved Bone Regeneration
- Improved Bone Strength
- Improved Bone Turnover Marker
- Improved Bone Volume
- Improved Calcium Absorption
- Improved Calcium Retention
- Improved Femoral Neck Bone Mineral Density
- Improved Hip Joint Bone Mineral Density
- Improved Jump Height
- Improved Lower-Body Muscular Strength
- Improved Lumbar Bone Mineral Density
- Improved Magnesium Bioaccessibility
- Improved Mechanical Properties
- Improved Nutrient Retention
- Improved Resistance Exercise Performance
- Improved Strength Performance
- Improved Total Volumetric Bone Mineral Density
- Improved Trabecular Number
- Improved Vitamin D Levels
- Increased Bone-Specific Alkaline Phosphatase Level
- Increased Carboxylated Osteocalcin Level
- Increased Carboxylated Osteocalcin Ratio
- Increased Gamma-Carboxylated Osteocalcin Levels
- Increased Plasma Vitamin K Levels
- Maintained Cross-Linked Telopeptide of Type 1 Collagen Level
- Osteoporosis Prevention
- Osteoporosis Treatment Strategy
- Prevented Bone Loss
- Prevented Sarcopenia
- Reduced Aging Effects
- Reduced Beta-CrossLap
- Reduced Biochemical Parameter Level
- Reduced Bone Alkaline Phosphatase
- Reduced Bone Loss
- Reduced Bone Turnover
- Reduced Bone-Specific Alkaline Phosphatase Level
- Reduced Fracture Incidence
- Reduced Osteoporotic Fracture Risk
- Reduced P1NP Level
- Reduced Procollagen Type 1 N Propeptide Level
- Reduced Risk of Low Bone Mineral Density
- Reduced Risk of Osteoporotic Fractures
- Reduced Shell Breaking Strength
- Reduced Urine Deoxypyridinoline Levels
- Reduced Vitamin D Deficiency
- Stable Lumbar Bone Mineral Density
- Strengthened Musculoskeletal System